GlassScriptPhysician profile
Christian Scheufele
NPI 1174014195
$26,048.25
in general payments reported to CMS, 2019-2025
32 companies · $5,771 in 2025
The $5,771 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $131 · 2021: $1,642 · 2022: $4,430 · 2023: $6,199 · 2024: $7,596 · 2025: $5,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Consulting Fee: $1,103 · Education: $282 · Travel and Lodging: $67.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,114.31 |
| Consulting Fee | $1,102.50 |
| Education | $282.16 |
| Travel and Lodging | $67.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,855.25 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $2,908.51 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $2,206.96 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $1,979.18 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $1,875.45 | 2020-2025 | |
| Janssen Biotech, INC. | $1,833.20 | 2020-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $1,614.37 | 2021-2025 | Ilumya, Winlevi, Blu-U |
| Regeneron Healthcare Solutions, INC. | $932.75 | 2022-2025 | Dupixent, Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $764.78 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $739.89 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $714.10 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Ucb, INC. | $685.82 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $651.44 | 2022-2025 | |
| Incyte Corporation | $624.09 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $541.12 | 2022-2025 | Sotyktu |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $434.25 | 2023-2025 | Zoryve |
| Johnson & Johnson Health Care Systems INC. | $388.95 | 2022-2025 | Tremfya |
| Amgen INC. | $350.29 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $323.37 | 2022-2025 | Arazlo, Cabtreo, Siliq |
| Kyowa Kirin, INC. | $308.46 | 2022-2024 | Poteligeo |
| Leo Pharma INC. | $299.07 | 2022-2025 | Adbry, Anzupgo |
| Sandoz INC. | $243.44 | 2023 | Hyrimoz |
| Biofrontera INC. | $161.14 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Blueprint Medicines Corporation | $156.18 | 2024-2025 | Ayvakit |
| Organon LLC | $136.23 | 2025 | Vtama |
| Almirall LLC | $122.72 | 2025 | Klisyri |
| Fresenius Kabi USA, LLC | $87.42 | 2023-2024 | Idacio |
| Helsinn Therapeutics (U.S.), INC. | $37.49 | 2021 | |
| Tactile Systems Technology INC | $21.26 | 2024 | Flexitouch Plus, Entre Plus |
| Journey Medical Corporation | $20.20 | 2025 | |
| Genentech USA, INC. | $15.83 | 2025 | Xolair |
| Biowound Solutions, INC. | $15.04 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Scheufele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.